ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?

Lipids in Health and Disease

Doris Hendig¹  Cornelius Knabbe¹  Christian Götting²  Isabel Faust¹  Mareike Dabisch-Ruthe¹  Joachim Kuhn¹  Patricia Kuzaj¹ 

[1] Herz- und Diabeteszentrum NRW, Institut für Laboratoriums- und Transfusionsmedizin, Universitätsklinik der Ruhr-Universität Bochum, Georgstraße 11, 32 545 Bad Oeynhausen, Germany;MVZ Labor Limbach Nürnberg, Lina-Ammon-Straße 28, 90471 Nürnberg, Germany

关键词: APOE;    LDLR;    PCSK9;    SREBP2;    HMG CoA reductase;    Atherosclerosis;    Cholesterol biosynthesis;    ABCC6;    ABC transporter;    Pseudoxanthoma elasticum;   

Others  :  1159971
DOI  :  10.1186/1476-511X-13-118

 received in 2014-05-20, accepted in 2014-07-17,  发布年份 2014

【 摘 要 】

Background

Dysregulations in cholesterol and lipid metabolism have been linked to human diseases like hypercholesterolemia, atherosclerosis or the metabolic syndrome. Many ABC transporters are involved in trafficking of metabolites derived from these pathways. Pseudoxanthoma elasticum (PXE), an autosomal-recessive disease caused by ABCC6 mutations, is characterized by atherogenesis and soft tissue calcification.

Methods

In this study we investigated the regulation of cholesterol biosynthesis in human dermal fibroblasts from PXE patients and healthy controls.

Results

Gene expression analysis of 84 targets indicated dysregulations in cholesterol metabolism in PXE fibroblasts. Transcript levels of ABCC6 were strongly increased in lipoprotein-deficient serum (LPDS) and under serum starvation in healthy controls. For the first time, increased HMG CoA reductase activities were found in PXE fibroblasts. We further observed strongly elevated transcript and protein levels for the proprotein convertase subtilisin/kexin type 9 (PCSK9), as well as a significant reduction in APOE mRNA expression in PXE.

Conclusion

Increased cholesterol biosynthesis, elevated PCSK9 levels and reduced APOE mRNA expression newly found in PXE fibroblasts could enforce atherogenesis and cardiovascular risk in PXE patients. Moreover, the increase in ABCC6 expression accompanied by the induction of cholesterol biosynthesis supposes a functional role for ABCC6 in human lipoprotein and cholesterol homeostasis.

【 授权许可】

   
2014 Kuzaj et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Ueda K: ABC proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem 2011, 75:401-409.
• [2]Uitto J: The gene family of ABC transporters-novel mutations, new phenotypes. Trends Mol Med 2005, 11:341-343.
• [3]Tarling EJ, Vallim TQ, Edwards PA: Role of ABC transporters in lipid transport and human disease. Trends Endocrinol Metabol 2013, 24:342-350.
• [4]Vanakker OM, Hosen MJ, De Paepe A: The ABCC6 transporter: what lessons can be learnt from other ATP-binding cassette transporters? Front Genet 2013, 4(203):1-6.
• [5]Prunier F, Terrien G, Le Corre Y, Apana AL, Bière L, Kauffenstein G, Furber A, Bergen AA, Gorgels TG, Le Saux O, Leftheriotis G, Martin L: Pseudoxanthoma Elasticum: Cardiac Findings in Patients and Abcc6-Deficient Mouse Model. PLoS One 2013, 8:e68700.
• [6]Hendig D, Knabbe C, Götting C: New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers. Front Genet 2013, 4(114):1-6.
• [7]Ronchetti I, Boraldi F, Annovi G, Cianciulli P, Quaglino D: Fibroblast involvement in soft connective tissue calcification. Front Genet 2013, 4(22):1-16.
• [8]Maccari F, Volpi N: Structural characterization of the skin glycosaminoglycans in patients with pseudoxanthoma elasticum. Int J Dermatol 2008, 47:1024-1027.
• [9]Hendig D, Schulz V, Arndt M, Szliska C, Kleesiek K, Götting C: Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clin Chem 2006, 52:227-234.
• [10]Váradi A, Szabó Z, Pomozi V, de Boussac H, Fülöp K, Arányi T: ABCC6 as a target in pseudoxanthoma elasticum. Curr Drug Targets 2011, 12:671.
• [11]Plomp AS, Toonstra J, Bergen AA, van Dijk MR, de Jong PT: Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A 2010, 152:1049-1058.
• [12]Vermeer BJ, Mateysen AA, van Gent CM, van Sabben RM, Emeis JJ: The lipid composition and localization of free and esterified cholesterol in different types of xanthomas. J Investig Dermatol 1982, 78:305-308.
• [13]Neidner KH, Martinez-Hernandez A: Localized acquired cutaneous pseudoxanthoma elasticum. J Am Acad Dermatol 1979, 1:523-530.
• [14]Podet EJ, Shaffer DR, Gianturco SH, Bradley WA, Yang CY, Guyton JR: Interaction of low density lipoproteins with human aortic elastin. Arterioscler Thromb Vasc Biol 1991, 11:116-122.
• [15]Srinivasan S, Yost C, Radhakrishnamurthy B, Dalferes E, Berenson G: Lipoprotein-elastin interactions in human aorta fibrous plaque lesions. Atherosclerosis 1981, 38:137-147.
• [16]Bergen AA, Plomp AS, Hu X, de Jong PT, Gorgels TG: ABCC6 and pseudoxanthoma elasticum. Pflügers Arch Eur J Physiol 2007, 453:685-691.
• [17]Beck K, Hayashi K, Nishiguchi B, Le Saux O, Hayashi M, Boyd CD: The distribution of Abcc6 in normal mouse tissues suggests multiple functions for this ABC transporter. J Histochem Cytochem 2003, 51:887-902.
• [18]Hendig D, Langmann T, Kocken S, Zarbock R, Szliska C, Schmitz G, Kleesiek K, Götting C: Gene expression profiling of ABC transporters in dermal fibroblasts of pseudoxanthoma elasticum patients identifies new candidates involved in PXE pathogenesis. Lab Invest 2008, 88:1303-1315.
• [19]Boraldi F, Quaglino D, Croce M, Garcia Fernandez M, Tiozzo R, Gheduzzi D, Bacchelli B, Pasquali Ronchetti I: Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol 2003, 22:491-500.
• [20]Gorgels TG, Hu X, Scheffer GL, Van der Wal AC, Toonstra J, de Jong PT, Van Kuppevelt TH, Levelt CN, de Wolf A, Loves WJ, Scheper RJ, Peek R, Bergen AA: Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet 2005, 14:1763-1773.
• [21]Klement JF, Matsuzaki Y, Jiang Q-J, Terlizzi J, Choi HY, Fujimoto N, Li K, Pulkkinen L, Birk DE, Sundberg JP, Uitto J: Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol 2005, 25:8299-8310.
• [22]Fülöp K, Jiang Q, Pomozi V, Szabó PT, Arányi T, Sarkadi B, Borst P, Uitto J, Váradi A: ABCC6 does not transport vitamin K3-glutathione conjugate from the liver: relevance to pathomechanisms of pseudoxanthoma elasticum. Biochem Biophys Res Commun 2011, 415:468-471.
• [23]Szabó Z, Váradi A, Li Q, Uitto J: ABCC6 does not transport adenosine—Relevance to pathomechanism of pseudoxanthoma elasticum. Mol Genet Metab 2011, 104:421.
• [24]Markello TC, Pak LK, St Hilaire C, Dorward H, Ziegler SG, Chen MY, Chaganti K, Nussbaum RL, Boehm M, Gahl WA: Vascular pathology of medial arterial calcifications in NT5E deficiency: Implications for the role of adenosine in pseudoxanthoma elasticum. Mol Genet Metab 2011, 103:44-50.
• [25]Borst P, van de Wetering K, Schlingemann R: Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery? Cell Cycle 2008, 7:1575-1579.
• [26]Voloshyna I, Reiss AB: The ABC transporters in lipid flux and atherosclerosis. Prog Lipid Res 2011, 50:213-224.
• [27]Wang J, Near S, Young K, Connelly PW, Hegele RA: ABCC6 gene polymorphism associated with variation in plasma lipoproteins. J Hum Genet 2001, 46:699-705.
• [28]Peloso GM, Demissie S, Collins D, Mirel DB, Gabriel SB, Cupples LA, Robins SJ, Schaefer EJ, Brousseau ME: Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res 2010, 51:3524-3532.
• [29]Schulz V, Hendig D, Henjakovic M, Szliska C, Kleesiek K, Götting C: Mutational analysis of the ABCC6 gene and the proximal ABCC6 gene promoter in German patients with pseudoxanthoma elasticum (PXE). Hum Mutat 2006, 27:831.
• [30]Pohl A, Devaux PF, Herrmann A: Function of prokaryotic and eukaryotic ABC proteins in lipid transport. Biochim Biophys Acta Mol Cell Biol Lipids 2005, 1733:29-52.
• [31]Guo H, Li Q, Chou DW, Uitto J: Atorvastatin counteracts aberrant soft tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6−/−). J Mol Med 2013, 91:1-8.
• [32]Lamon-Fava S: Statins and lipid metabolism: an update. Curr Opin Lipidol 2013, 24:221-226.
• [33]Vaya J: The association between biomarkers in the blood and carotid plaque composition-focusing on oxidized lipids, oxysterols and plaque status. Biochem Pharmacol 2013, 86:15-18.
• [34]Khaidakov M, Mitra S, Wang X, Ding Z, Bora N, Lyzogubov V, Romeo F, Schichman SA, Mehta JL: Large impact of low concentration oxidized LDL on angiogenic potential of human endothelial cells: a microarray study. PLoS One 2012, 7:e47421.
• [35]Urban D, Pöss J, Böhm M, Laufs U: Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013, 62:1401-1408.
• [36]Gibson K, Hoffmann G, Schwall A, Broock R, Aramaki S, Sweetman L, Nyhan W, Brandt I, Wappner R, Lehnert W: 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured fibroblasts from patients with mevalonate kinase deficiency: differential response to lipid supplied by fetal bovine serum in tissue culture medium. J Lipid Res 1990, 31:515-521.
• [37]Faust I, Roch C, Kuhn J, Prante C, Knabbe C, Hendig D: Human xylosyltransferase-I-a new marker for myofibroblast differentiation in skin fibrosis. Biochem Biophys Res Commun 2013, 436:449-454.
• [38]Kuzaj P, Kuhn J, Faust I, Knabbe C, Hendig D: Measurement of HMG CoA reductase activity in different human cell lines by ultra-performance liquid chromatography tandem mass spectrometry. Biochem Biophys Res Commun 2014, 443:641-645.
• [39]Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Wittwer CT, Schjerling P, Day PJ, Abreu M, Aguado B, Beaulieu JF, Beckers A, Bogaert S, Browne JA, Carrasco-Ramiro F, Ceelen L, Ciborowski K, Cornillie P, Coulon S, Cuypers A, De Brouwer S, De Ceuninck L, De Craene J, De Naeyer H, De Spiegelaere W, et al.: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
• [40]Wenham P, Price W, Blundell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991, 337:1158-1159.
• [41]Levy E, Ouadda ABD, Spahis S, Sane AT, Garofalo C, Grenier É, Emonnot L, Yara S, Couture P, Beaulieu J-F, Ménard D, Seidah NG, Elchebly M: PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 2013, 227:297-306.
• [42]Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR: Post-analysis follow-up and validation of microarray experiments. Nat Genet 2002, 32:509-514.
• [43]Boraldi F, Annovi G, Vermeer C, Schurgers LJ, Trenti T, Tiozzo R, Guerra D, Quaglino D: Matrix gla protein and alkaline phosphatase are differently modulated in human dermal fibroblasts from PXE patients and controls. J Investig Dermatol 2013, 133:946-954.
• [44]Le Saux O, Bunda S, VanWart CM, Douet V, Got L, Martin L, Hinek A: Serum factors from pseudoxanthoma elasticum patients alter elastic fiber formation in vitro. J Investig Dermatol 2006, 126:1497-1505.
• [45]Quaglino D Jr, Boraldi F, Barbieri D, Croce A, Tiozzo R, Pasquali Ronchetti I: Abnormal phenotype of in vitro dermal fibroblasts from patients with pseudoxanthoma elasticum (PXE). Biochim Biophys Acta Mol Basis Dis 2000, 1501:51-62.
• [46]Quaglino D, Boraldi F, Annovi G, Ronchetti I: The multifaceted complexity of genetic diseases: a lesson from pseudoxanthoma elasticum. Adv Stud Genet Disord 2011, 15:289-318.
• [47]Uitto J, Li Q, Jiang Q: Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J Investig Dermatol 2009, 130:661-670.
• [48]Zhao C, Dahlman-Wright K: Liver X receptor in cholesterol metabolism. J Endocrinol 2010, 204:233-240.
• [49]Goedeke L, Fernández-Hernando C: Regulation of cholesterol homeostasis. Cell Mol Life Sci 2012, 69:1-16.
• [50]Brown MS, Dana SE, Goldstein JL: Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins. Proc Natl Acad Sci 1973, 70:2162-2166.
• [51]Brown M, Dana S, Goldstein J: Cholesterol ester formation in cultured human fibroblasts. Stimulation by oxygenated sterols. J Biol Chem 1975, 250:4025-4027.
• [52]Luft FC: Pseudoxanthoma elasticum and statin prophylaxis. J Mol Med 2013, 91:1-2.
• [53]Shiping L, Lorenzen ED, Fumagalli M, Li B, Harris K, Xiong Z, Zhou L, Korneliussen TS, Somel M, Babbitt C, Wray G, Li J, He W, Wang Z, Fu W, Xiang X, Morgan CC, Doherty A, O’Connell MJ, McInerney JO, Born EW, Dalen L, Dietz RD, Orlando L, Sonne CS, Zhang G, Nielsen R, Willerslev E, Wang JW: Population Genomics Reveal Recent Speciation and Rapid Evolutionary Adaptation in Polar Bears. Cell 2014, 157:785-794.
• [54]Pisciotta L, Tarugi P, Borrini C, Bellocchio A, Fresa R, Guerra D, Quaglino D, Ronchetti I, Calandra S, Bertolini S: Pseudoxanthoma elasticum and familial hypercholesterolemia: A deleterious combination of cardiovascular risk factors. Atherosclerosis 2010, 210:173-176.
• [55]Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Di Y, Shetterly S, Arimura Z, Salomonis H, Romanow WG, Thibault ST, Zhang R, Cao P, Yang XP, Yu T, Lu M, Retter MW, Kwon G, Henne K, Pan O, Tsai MM, Fuchslocher B, Yang E, Zhou L, Lee KJ, et al.: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci 2009, 106:9820-9825.
• [56]Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J: Peroxisome proliferator-activated receptor gamma activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem 2012, 287:23667-23677.
• [57]Bedi M, Niesen M, Lopez D: Inhibition of squalene synthase upregulates PCSK9 expression in rat liver. Arch Biochem Biophys 2008, 470:116-119.
• [58]Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B: Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008, 582:949-955.
• [59]Beyea MM, Reaume S, Sawyez CG, Edwards JY, O’Neil C, Hegele RA, Pickering JG, Huff MW: The oxysterol 24 (S), 25-epoxycholesterol attenuates human smooth muscle-derived foam cell formation via reduced low-density lipoprotein uptake and enhanced cholesterol efflux. J Am Heart Assoc 2012, 1:e000810.
• [60]de Boussac H, Ratajewski M, Sachrajda I, Köblös G, Tordai A, Pulaski L, Buday L, Váradi A, Arányi T: The ERK1/2-hepatocyte nuclear factor 4 alpha axis regulates human ABCC6 gene expression in hepatocytes. J Biol Chem 2010, 285:22800-22808.
• [61]van Dijk KW, van Vlijmen BJ, van’t Hof HB, van der Zee A, Santamarina-Fojo S, van Berkel TJ, Havekes LM, Hofker MH: In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J Lipid Res 1999, 40:336-344.
• [62]Dergunov A: Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: Mechanistic and clinical studies. Biomed Pharmacother 2011, 65:597-603.
• [63]Cerda A, Genvigir FD, Willrich MA, Arazi SS, Bernik M, Dorea EL, Bertolami MC, Faludi AA, Hirata MH, Hirata RD: Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin. Lipids Health Dis 2011, 10:1-11.
• [64]Quinn C, Kagedal K, Terman A, Stroikin U, Brunk U, Jessup W, Garner B: Induction of fibroblast apolipoprotein E expression during apoptosis, starvation-induced growth arrest and mitosis. Biochem J 2004, 378:753-761.
• [65]Ishibashi M, Masson D, Westerterp M, Wang N, Sayers S, Li R, Welch CL, Tall AR: Reduced VLDL clearance in Apoe−/− Npc1−/− mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels. J Lipid Res 2010, 51:2655-2663.
• [66]Masliah E, Mallory M, Veinbergs I, Miller A, Samuel W: Alterations in apolipoprotein E expression during aging and neurodegeneration. Prog Neurobiol 1996, 50:493-503.
• [67]Ganfornina MD, Do Carmo S, Lora JM, Torres-Schumann S, Vogel M, Allhorn M, González C, Bastiani MJ, Rassart E, Sanchez D: Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell 2008, 7:506-515.
• [68]Bajo-Grañeras R, Sanchez D, Gutierrez G, González C, Do Carmo S, Rassart E, Ganfornina MD: Apolipoprotein D alters the early transcriptional response to oxidative stress in the adult cerebellum. J Neurochem 2011, 117:949-960.
• [69]Li Q, Jiang Q, Schurgers LJ, Uitto J: Pseudoxanthoma elasticum: Reduced gamma-glutamyl carboxylation of matrix gla protein in a mouse model (Abcc6−/−). Biochem Biophys Res Commun 2007, 364:208-213.
• [70]Ali Z, Heverin M, Olin M, Acimovic J, Lövgren-Sandblom A, Shafaati M, Båvner A, Meiner V, Leitersdorf E, Björkhem I: On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and cyp27a1−/− mice. J Lipid Res 2013, 54:1033-1043.
• [71]Hall E, Ren S, Hylemon P, Redford K, Del Castillo A, Gil G, Pandak W: Mitochondrial cholesterol transport: a possible target in the management of hyperlipidemia. Lipids 2005, 40:1237-1244.
• [72]Xiaoping Z, Fajun Y: Regulation of SREBP-mediated gene expression. Sheng Wu Wu Li Hsueh Bao 2012, 28:287.
• [73]Xiao X, Song B-L: SREBP: a novel therapeutic target. Acta Biochim Biophys Sin 2013, 45:2-10.
• [74]Meng Z, Yin Y, Lv J, Sha M, Lin Y, Gao L, Zhu Y, Sun Y, Han X: Aberrant activation of liver X receptors impairs pancreatic beta cell function through upregulation of sterol regulatory element-binding protein 1c in mouse islets and rodent cell lines. Diabetologia 2012, 55:1-12.
• [75]Douet V, Van Wart CM, Heller MB, Reinhard S, Le Saux O: HNF4 alpha and NF-E2 are key transcriptional regulators of the murine Abcc6 gene expression. Biochim Biophys Acta Gene Struct Expr 2006, 1759:426-436.
• [76]Kobayashi M, Gouda K, Chisaki I, Asada K, Ogura J, Takahashi N, Konishi T, Koshida Y, Sasaki S, Yamaguchi H, Iseki K: Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: Involvement of SREBP-mediated gene regulation. Int J Pharm 2013, 452:36-41.